No Data
Cocrystal Pharma (COCP) Receives a Buy From Noble Financial
Express News | Cocrystal Pharma Inc: No Clinically Significant Observations Were Noted in Laboratory Assessments, Physical Exams or Electrocardiograms
Express News | Cocrystal Pharma Inc: All Participants Completed Study With No Discontinuations
Express News | Cocrystal Pharma Reports Favorable Results From Single-Ascending Dose Cohorts of Phase 1 Study With Cdi-988, Its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
Noble Financial Maintains Cocrystal Pharma(COCP.US) With Buy Rating, Maintains Target Price $10
Noble Financial analyst Robert LeBoyer maintains $Cocrystal Pharma(COCP.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 26.4
Express News | New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza a May Be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows
No Data